Systemic Haemostats header image Systemic Haemostats header image
Systemic Haemostatic Technology

Haemostatix has developed a systemic platelet substitute technology. An experimental prototype, HaemoPlax, has been developed that consists of microparticles linked to a fibrinogen-binding peptide sequence (Gly Pro Arg Pro "GPRP"). Multiple GPRP peptides are bound to the surface of the microparticle (Figure A below). On administration via infusion, the product binds patient fibrinogen via the GPRP sequence (Figure B). HaemoPlax circulates the body with bound fibrinogen until it meets activated platelets at the site of a wound or lesion. The product then binds to platelets via fibrinogen 'bridges', to form a thrombus (Figure C). The action of thrombin results in fibrin cross-linking throughout the HaemoPlax-platelet thrombus to form an effective clot. Thus where platelet counts are low, HaemoPlax helps to form an effective haemostatic plug over the wound or lesion.

In a second prototype, HXTC 901, the GPRP sequence is protected by a thrombin-cleavable peptide component. The product circulates without binding fibrinogen, until it arrives at a wound site, where in the presence of thrombin, the GPRP sequence is exposed, allowing binding to fibrinogen.


Systemic Haemostats